IMDC Risk Model for Metastatic RCC
Loading...
References
- T Powles. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.. Annals of oncology : official journal of the European Society for Medical Oncology, 2024
- J B A G Haanen. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.. ESMO open, 2023
- Daniela Lee. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.. European urology, 2023
- W. Rathmell. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022
- T Powles. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.. Annals of oncology : official journal of the European Society for Medical Oncology, 2021
- R. Kotecha. Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma.. Journal of the National Comprehensive Cancer Network : JNCCN, 2021
- B. Pérez-Valderrama. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.. Annals of oncology : official journal of the European Society for Medical Oncology, 2016
- J. Ko. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.. The Lancet. Oncology, 2015
- D. Heng. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.. The Lancet. Oncology, 2013
- N. Kroeger. Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
- Reference - 10.1016/j.annonc.2024.05.537\
- Reference - 10.6004/jnccn.2022.0001\
- Reference - 10.1016/j.eururo.2023.01.001\